Search by Journal
- HOME
- > Search by Journal
- > Journal of Japanese Society of Pharmaceutical Oncology
Journal of Japanese Society of Pharmaceutical Oncology
Volume 20, Issue / 2021
English Article 
Japanese Article- Please note that metadata of J-type articlesare generated by machine-translation and the original texts are written in Japanese.
|
O-1. The peripheral blood lymphocyte counts become the onset prediction biomarker of the nivolumab-induced immune-mediated side effect: Look at the multicenter rear; a mark observational study 江上彩映香, 河添仁, 橋本浩伸, 魚住龍史, 荒見透子, 先山奈緒美, 大江裕一郎, 中田英夫, 青森達, 池村辰之介, 福永興壱, 山口正和, 中村智徳 Journal of Japanese Society of Pharmaceutical Oncology 20: 1-1, 2021. |
|---|
|
|
O-2. Search - of the effect that a concomitant drug gives for diarrhea by predictor - naldemedine about the onset of diarrhea after the naldemedine introduction 塩尻恭平, 橋詰淳哉, 河内佑樹, 江崎のぞみ, 長谷川京子, 神田紘介, 龍恵美, 石井浩二, 山下春奈, 佐々木均, 兒玉幸修 Journal of Japanese Society of Pharmaceutical Oncology 20: 2-2, 2021. |
|---|
|
|
O-3. The elucidation of the retching risk factor by the oxycodone extended-release and construction of the risk estimate model using the machine learning 熊井正貴, 今井俊吾, 加藤信太郎, 小柳遼, 敦賀健吉, 山田武宏, 武隈洋, 菅原満 Journal of Japanese Society of Pharmaceutical Oncology 20: 3-3, 2021. |
|---|
|
|
O-4. Investigation of a follow-up during the Lenvatinib medication period in the health insurance pharmacy and the effect on medical treatment by the medical cooperation using the tracing report 穗積利恵, 久田健登, 加藤博昭, 石川遥介, 亀山俊, 堀口雅巳 Journal of Japanese Society of Pharmaceutical Oncology 20: 4-4, 2021. |
|---|
|
|
O-5. Recognition investigation of the pharmacist for the cancer reproductive medicine in Saitama 伊藤剛貴, 伊藤幸, 国吉央城, 畠山朋樹, 藤堂真紀, 相川晴彦, 川田亮, 中山季昭, 島田雅弘, 鈴木栄, 源川良一, 北澤貴樹 Journal of Japanese Society of Pharmaceutical Oncology 20: 5-5, 2021. |
|---|
|
|
O-6. The effect of the concomitant drug on effectiveness of nivolumab and the Pembrolizumab: Look at the single institution rear; a mark observational study 荻原利章, 河添仁, 江上彩映香, 橋本浩伸, 先山奈緒美, 大江裕一郎, 山口正和, 平賀ゆい, 横山雄太, 鈴木小夜, 中村智徳 Journal of Japanese Society of Pharmaceutical Oncology 20: 6-6, 2021. |
|---|
|
|
O-7. Evaluation of the Carboplatin doses calculation method in the intracranial germ cell neoplasm 常田百合, 熊倉康郎, 高木麻衣, 井上理香子, 千崎康司, 谷口理恵子, 村松秀城, 高橋義行, 大岡史治, 本村和也, 夏目敦至, 若林俊彦, 山田清文 Journal of Japanese Society of Pharmaceutical Oncology 20: 7-7, 2021. |
|---|
|
|
O-8. Characteristic of the antitumor agents in the side effect report 佐々木弘恒 Journal of Japanese Society of Pharmaceutical Oncology 20: 8-8, 2021. |
|---|
|
|
O-9. The effect that distance gives to the thromboembolism onset after the subcutaneous burying type central veins port custody in the days until a bevacizumab administration start 吉野真樹, 田中佳美, 大平直樹, 榑松尚子, 佐々木奈穂, 田川千明, 勝山里佳, 木村宏之, 山下弘毅, 石井良, 大倉裕二, 瀧井康公 Journal of Japanese Society of Pharmaceutical Oncology 20: 9-9, 2021. |
|---|
|
|
O-10. Evaluation of the measurement and the effect level measurement of the effect level in the chemotherapy of the unresectable pancreatic cancer between the types of job 田内淳子, 篠原旭, 川崎敏克 Journal of Japanese Society of Pharmaceutical Oncology 20: 10-10, 2021. |
|---|
|
|
O-11. Usefulness of the supportive care standardization in the breast cancer adjuvant postoperative treatment (TC therapy) 中川武史, 戸塚弘幸, 高橋喜統, 井口雅史, 政氏藤玄 Journal of Japanese Society of Pharmaceutical Oncology 20: 11-11, 2021. |
|---|
|
|
O-12. Fact-finding about retching of L-Asparaginase 桑原清人, 秋葉昌克, 木内直美, 大谷美子, 武内正博 Journal of Japanese Society of Pharmaceutical Oncology 20: 12-12, 2021. |
|---|
|
|
O-13. The effect that the pressure therapy using the surgical glove gives to supportive care drug costs of chemotherapy-induced peripheral neuropathy 樋口浩輔, 斎藤祐輔, 福田愛弓, 木村謙吾, 加藤浩, 水野豊 Journal of Japanese Society of Pharmaceutical Oncology 20: 13-13, 2021. |
|---|
|
|
O-14. Examination of the anticholinergic drug prophylaxis at the irinotecan administration in our hospital 近藤雅, 江尻将之, 黒瀬優輔, 春日井悠司, 竹内正幸, 大西正文 Journal of Japanese Society of Pharmaceutical Oncology 20: 14-14, 2021. |
|---|
|
|
O-15. The effect that lymphocytopenia in the breast cancer dose-dense chemotherapy gives to the PCP onset 春日井悠司, 江尻将之, 黒瀬優輔, 近藤雅, 竹内正幸, 大西正文 Journal of Japanese Society of Pharmaceutical Oncology 20: 15-15, 2021. |
|---|
|
|
O-16. Examination multicenter rearward research about the effectiveness and the safety of the nivolumab in patients with stomach cancer 畠山智明, 高崎修一, 梅原健吾, 佐藤友昭, 鈴木直哉, 宇野健一, 井上靖隆, 渡邉大毅, 畠中仁大, 伊佐治麻里子, 太田明秀, 元茂拓法, 徳留章, 藤井達郎, 神垣輝美, 曽我部進 Journal of Japanese Society of Pharmaceutical Oncology 20: 16-16, 2021. |
|---|
|
|
O-17. We look at the rear of the effect on infusio reaction prevention of the pre-medication for the pertuzumab combination therapy and examine a mark 新田悠一朗, 中谷彰規, 西井智成, 岩山邦典, 加藤千晴, 高橋芳子, 清水知沙, 鎌仲知美, 鈴木玲奈, 尾崎靖子, 小野尚志, 山下恭範, 鳥本悦宏, 中馬真幸, 田崎嘉一 Journal of Japanese Society of Pharmaceutical Oncology 20: 17-17, 2021. |
|---|
|
|
O-18. Efforts and the current situation to patients who received foreign cancer chemotherapy in the Kitano Hospital 水田純平, 近藤篤, 三宅麻文, 中多陽子, 河原宏之, 石川弘子, 尾上雅英 Journal of Japanese Society of Pharmaceutical Oncology 20: 18-18, 2021. |
|---|
|
|
O-19. Example that we managed pharmaceutical for cancer-treated patients foreign by pharmaceutical medicine cooperation utilizing the ICT 松浦綾子, 尾形晶子, 櫻井裕子, 小泉浩司, 大上満, 加藤亜由美, 倉島信彦, 日向幸恵, 藤田尚宏 Journal of Japanese Society of Pharmaceutical Oncology 20: 19-19, 2021. |
|---|
|
|
O-20. One patient whom tardive neutropenia was found in during Abemaciclib administration 島貫裕実子, 下村昭彦, 小川千晶, 寺門浩之, 清水千佳子 Journal of Japanese Society of Pharmaceutical Oncology 20: 20-20, 2021. |
|---|
|
|
O-21. It is an example with suspected onset of drug induced hepatic injury with the chemoradiotherapy after the head and neck cancer technique 村田志帆, 鎌田隼, 松山千容, 金子明日美, 鈴木真也, 池田公史, 田原信, 川崎敏克 Journal of Japanese Society of Pharmaceutical Oncology 20: 21-21, 2021. |
|---|
|
|
O-22. One case of the extensive-stage small cell lung cancer given Atezolizumab and Carboplatin and etoposide combination therapy under the maintenance dialysis 宮本佳奈, 櫻下弘志, 佐伯康之, 友田江美, 中島春佳, 野津和良, 古川千紗, 泉谷悟, 松尾裕彰 Journal of Japanese Society of Pharmaceutical Oncology 20: 22-22, 2021. |
|---|
|
|
O-23. An example of patients with AYA generation chronic myelogenous leukemia that succeeded for the opioid perfection secession after opioid dependence developed with oxycodone of the pain relief purpose 加藤真也, 鈴木祐介, 和久田智靖, 櫻井飛鳥, 内藤隆文, 山末英典, 川上純一 Journal of Japanese Society of Pharmaceutical Oncology 20: 23-23, 2021. |
|---|
|
|
O-24. About health insurance pharmacy pharmacist Hospital training mainly on cancer treatment in the Masuda Red Cross hospital 吉田勝好, 小畑志保, 永戸辰弥, 篠原由美, 田原明子, 郷原学 Journal of Japanese Society of Pharmaceutical Oncology 20: 24-24, 2021. |
|---|
|
|
O-25. Relation of the consciousness change of patients, the family for the home care and the at-home visit pharmacist 星利佳, 齋藤智美 Journal of Japanese Society of Pharmaceutical Oncology 20: 25-25, 2021. |
|---|
|
|
O-26. A function and cancer treatment of the specialized medical institution cooperation drugstore 串田一樹, 白石丈也, 今城宏文, 谷川大夢, 廣原正宜 Journal of Japanese Society of Pharmaceutical Oncology 20: 26-26, 2021. |
|---|
|
|
O-27. Research of the tracing report about the side effect for people of hospital business studies (cancer domain) completion 渡邉泰崇, 小森忠直, 伊藤昌裕, 宮田広樹, 福岡勝志, 弓削吏司 Journal of Japanese Society of Pharmaceutical Oncology 20: 27-27, 2021. |
|---|
|
|
O-28. Efforts for the improvement in quality to medication follow imposition and specific drug management instruction addition 2 角佳亮, 宮繁信一, 前原央奈 Journal of Japanese Society of Pharmaceutical Oncology 20: 28-28, 2021. |
|---|
|
|
O-29. Efforts to a cytokine-releasing syndrome with the treatment in our hospital 増田信一, 秋田賢宏, 望月伸夫, 米村雅人, 川崎敏克 Journal of Japanese Society of Pharmaceutical Oncology 20: 29-29, 2021. |
|---|
|
|
O-30. Examination of the appropriate infusion bottle pressure to reduce quantity of scattering at a preparation and the administration of injectable anticancer agent 柳澤友希, 黒須智博, 山下敦志, 夏目義明, 清野敏一, 伊佐間和郎, 西村哲治 Journal of Japanese Society of Pharmaceutical Oncology 20: 30-30, 2021. |
|---|
|
|
O-31. Role of the pharmacist as cancer genomic medicine coordinator (CGMC) in the cancer genomic medicine core base Hospital 中山晶子, 三牧幸代, 竹野美沙樹, 上本剛, 増田信一, 米村雅人, 川崎敏克, 向原徹, 土原一哉, 桑田健 Journal of Japanese Society of Pharmaceutical Oncology 20: 31-31, 2021. |
|---|
|
|
O-32. Efforts of the medicine medicine cooperation using the reporting book in the foreign chemotherapy 小川直希, 藤井千賀, 柳下祐貴子, 鶴島克将, 安井友佳子, 石坂敏彦 Journal of Japanese Society of Pharmaceutical Oncology 20: 32-32, 2021. |
|---|
|
|
O-33. One ... of patients with first CML that follow-up - medicine for cardiovascular adverse event medicine collaboration accompanied with the second generation TKI remedy in patients with CML was thought to be effective 西垣賢, 生川賀代, 米田勝晃 Journal of Japanese Society of Pharmaceutical Oncology 20: 33-33, 2021. |
|---|
|
|
O-34. The use actual situation and problem of the anticancer agent medication counseling sheet that hospital pharmacy and a local health insurance drugstore made in cooperation 喜田博美, 吉留実慧子, 財前美夏子, 平尾昂士, 吉岡幸洋, 井戸郷美, 槙原克也, 松村友和 Journal of Japanese Society of Pharmaceutical Oncology 20: 34-34, 2021. |
|---|
|
|
O-35. Efforts for the cancer chemotherapy cooperation full addition in the Hyogo Prefectural Kakogawa medical center 佐野隆大, 谷川千明, 大谷祐子, 柴田博子, 石川泰, 福井由美子 Journal of Japanese Society of Pharmaceutical Oncology 20: 35-35, 2021. |
|---|
|
|
O-36. Evaluation of the effect to give a hand-and-foot syndrome and quality of life of the capecitabine therapy by the cooperation of hospital pharmacist and the drugstore pharmacist 春名康裕, 中村暢彦, 喜多日向子, 一島知樹, 武田智子, 長谷川晃司, 矢野義孝, 楠本正明 Journal of Japanese Society of Pharmaceutical Oncology 20: 36-36, 2021. |
|---|
|
|
O-37. 1 case that we collaborated with a family circulatory organ physician for patients during foreign cancer chemotherapy, and a drugstore pharmacist was concerned with dose adjustment of the warfarin 溝上泰仁, 八坂瑞臣, 祖川倫太郎, 緒方健二, 嬉野博志, 藤田真衣, 山口尊則 Journal of Japanese Society of Pharmaceutical Oncology 20: 37-37, 2021. |
|---|
|
|
P-001. Clinical use by administration time shortening in the DRd, DVd therapy 高橋直也, 磯知輝, 小池道明, 菊地麻里 Journal of Japanese Society of Pharmaceutical Oncology 20: 38-38, 2021. |
|---|
|
|
P-002. The use situation of the opioid analgesic for the oropharynx mucositis that resulted from head and neck cancer chemoradiotherapy and rearward investigation about the gradual decrease period 黒木吟美, 松下尚弘, 野中敏治 Journal of Japanese Society of Pharmaceutical Oncology 20: 39-39, 2021. |
|---|
|
|
P-003. Rearward observational study (a large quantity of fluid replacement vs. short hydration) to compare the expression of AKI by the cisplatin and CKD by the hydration method 岩崎弘晃, 畠中仁大, 佐藤梨奈, 遠藤貴之, 菅野修平, 杉村大行, 山下順也, 小松燿, 佐々朋広, 泉克明, 千葉恵, 吉田知美, 川口ルミ子, 河井康孝 Journal of Japanese Society of Pharmaceutical Oncology 20: 40-40, 2021. |
|---|
|
|
P-004. The expression of Infusion Related Reaction situation investigation in the Elotuzumab administration 土屋貴之, 川崎和広, 秋山加菜, 粂哲雄, 吉嗣加奈子, 深谷真史, 榎並輝和, 多々良礼音, 篠道弘, 池田宇次 Journal of Japanese Society of Pharmaceutical Oncology 20: 41-41, 2021. |
|---|
|
|
P-005. Examination about the efforts of the Lenvatinib pharmacist outpatient department for the hepatocellular carcinoma 寺尾勇紀, 山関智恵, 加賀充朗, 渡邉一正, 三浦毅 Journal of Japanese Society of Pharmaceutical Oncology 20: 42-42, 2021. |
|---|
|
|
P-006. Investigation of the use situation of the immune checkpoint inhibitor in patients with lung cancer and the immune-mediated adverse event 町田梨絵子, 田中早穂子, 原友子, 野中敏治 Journal of Japanese Society of Pharmaceutical Oncology 20: 43-43, 2021. |
|---|
|
|
P-007. Fact-finding of the serum calcium concentrations drop with the denosumab administration to the decreased renal function patients 町田聖治, 長谷悠紀, 坪根未歩, 平野真健, 入江利行 Journal of Japanese Society of Pharmaceutical Oncology 20: 44-44, 2021. |
|---|
|
|
P-008. Look at the rear in the single institution of an effect, the side effect of the mirogabalin in patients with cancer; about mark examination 橋本百世, 見田秋与志, 田中育子, 仁木一順, 岡本禎晃 Journal of Japanese Society of Pharmaceutical Oncology 20: 45-45, 2021. |
|---|
|
|
P-009. The effectiveness of rituximab follower 2 for the grade non-Hodgkin's lymphoma during the recurrence and safe examination 佐分利美帆子, 三松史野, 目黒裕史, 大野恵一, 本多伸二, 小野勝, 村岡淳二 Journal of Japanese Society of Pharmaceutical Oncology 20: 46-46, 2021. |
|---|
|
|
P-010. The use situation investigation of the peg filgrastim in our hospital 渡辺麻里子, 藤原真亜子, 水嶋萌美, 草信晴美, 監物英男 Journal of Japanese Society of Pharmaceutical Oncology 20: 47-47, 2021. |
|---|
|
|
P-011. Blood toxicity expression investigation of the Atezolizumab + Carboplatin/etoposide therapy in patients with extensive-stage small-cell lung cancer 市原英則, 熊谷康平, 池上洋平, 村津圭治, 山下大輔, 別府博仁, 本田芳久 Journal of Japanese Society of Pharmaceutical Oncology 20: 48-48, 2021. |
|---|
|
|
P-012. Efforts and evaluation to the antiemesis therapy standardization in the gynecologic cancer CBDCA (AUC >= 4) component regimen 木村友美, 中村和行, 石川歩未, 阿部彩香, 高木竜一, 渡辺裕之, 石上仁美, 米山英二, 杉浦洋二 Journal of Japanese Society of Pharmaceutical Oncology 20: 49-49, 2021. |
|---|
|
|
P-013. About the treatment trend of patients who received colon cancer FOLFOXIRI+bevacizumab therapy 名坂輝子, 大和由美子, 吉田武史 Journal of Japanese Society of Pharmaceutical Oncology 20: 50-50, 2021. |
|---|
|
|
P-014. Investigations such as the use situation, and the like after the Osimertinib first treatment and the second treatment 津輕石玲於, 高橋典哉, 八重樫雅, 及川淳, 木村周古, 黒田祥嗣, 菊池英, 工藤琢身 Journal of Japanese Society of Pharmaceutical Oncology 20: 51-51, 2021. |
|---|
|
|
P-015. Examination about the association of the nivolumab-related hypoadrenalism and steroid administration history 足立紗知, 宮城和代, 仲野宏紀, 井上敦介, 宮部貴識, 山内一恭 Journal of Japanese Society of Pharmaceutical Oncology 20: 52-52, 2021. |
|---|
|
|
P-016. Analysis - using examination - tendency score of the effect of the Rabeprazole giving it to peripheral neuropathy with oxaliplatin 小林瑞希, 橋詰淳哉, 川瀬汐里, 古賀香織, 佐々木均, 兒玉幸修 Journal of Japanese Society of Pharmaceutical Oncology 20: 53-53, 2021. |
|---|
|
|
P-017. Search of the factor affecting infusion reaction expression at the Obinutuzumab administration 黒松誠, 梶田貴司, 樽野麻依, 西川豊, 赤坂尚司, 奥野智之 Journal of Japanese Society of Pharmaceutical Oncology 20: 54-54, 2021. |
|---|
|
|
P-018. Look at the steroid cumulative dose in cancer chemotherapy patients and the rear of the diabetes incidence; mark investigation - multicenter study - 小西郁代, 中井剛, 中村敏史, 吉村拓也, 鈴木善貴, 杉山みづほ, 徳田富妃子, 松下直樹, 坂野博紀, 村上仁志, 原田哲彦, 石川未奈子, 山口智江, 佐々木俊則, 堀田和男, 佐藤由美子, 板倉由縁, 山田清文 Journal of Japanese Society of Pharmaceutical Oncology 20: 55-55, 2021. |
|---|
|
|
P-019. Continuous pharmaceutical intervention by the pharmacist outpatient department to the Lenvatinib introduction patients for the hepatocellular carcinoma 原田靖基, 森本智, 中澤由依, 熊田拓史, 森下直紀, 戸祭庸子 Journal of Japanese Society of Pharmaceutical Oncology 20: 56-56, 2021. |
|---|
|
|
P-020. Investigation of the expression situation of precedent biomedicine at trastuzumab therapy initial introduction for patients with gastric cancer and Infusion Reaction of the bio follower product 仲田浩成, 三角紳博 Journal of Japanese Society of Pharmaceutical Oncology 20: 57-57, 2021. |
|---|
|
|
P-021. The irAE expression situation investigation with the immune checkpoint inhibitor 田中恭人, 森永崇史, 池沢若菜, 豊留麻衣, 北園幸大, 中野一馬, 山本梢, 屋敷大輔, 淵脇ゆかり, 徳丸章佳, 長ヶ原琢磨, 荻尾夕起子, 岸本真 Journal of Japanese Society of Pharmaceutical Oncology 20: 58-58, 2021. |
|---|
|
|
P-022. Investigation of the prescription situation of the hyperuricaemia therapeutic drug at acute myeloid leukemia start of therapy in our hospital 加藤雄也, 藤崎良一, 君和田貢 Journal of Japanese Society of Pharmaceutical Oncology 20: 59-59, 2021. |
|---|
|
|
P-023. Examination of the need of an evaluation of the side effect of Lenvatinib expression situation in patients with hepatocellular carcinoma and the intervention of the pharmacist 雅樂晏里沙, 金素安, 長谷川奈央, 金城直樹, 立沢正臣, 住吉正孝 Journal of Japanese Society of Pharmaceutical Oncology 20: 60-60, 2021. |
|---|
|
|
P-024. Continuous efforts of the side effect management for foreign oral anticancer medicine-treated patients 藤村拓也, 畑賢太, 斉藤俊英, 神垣輝美, 相馬まゆ子, 佐々木洋一, 今田愛也, 山本浩史 Journal of Japanese Society of Pharmaceutical Oncology 20: 61-61, 2021. |
|---|
|
|
P-025. Risk factor search of retching vomiting of the temozolomide combination chemoradiotherapy for patients with malignant glioma 高木麻衣, 熊倉康郎, 渡邉美菜子, 井上理香子, 宮崎雅之, 大岡史治, 本村和也, 夏目敦至, 若林俊彦, 山田清文 Journal of Japanese Society of Pharmaceutical Oncology 20: 62-62, 2021. |
|---|
|
|
P-026. Examination of the expression situation of the bleeding in docetaxel + ramucirumab combination therapy and the docetaxel monotherapy and the bleeding risk factor 松地里沙子, 角川幸男, 清水克次, 高木麻里, 吉田智江, 藤田敬子 Journal of Japanese Society of Pharmaceutical Oncology 20: 63-63, 2021. |
|---|
|
|
P-027. The expression situation of infusion reaction of precedent rituximab for the patients with follicular lymphoma in our hospital and following rituximab and safe examination 藤田愛美, 國東佑美, 渡邊小百合, 藤原康浩, 岸本靜佳, 鹿島孝子 Journal of Japanese Society of Pharmaceutical Oncology 20: 64-64, 2021. |
|---|
|
|
P-028. A nourishment evaluation before the treatment in Nivolumab treated patients and examination about the effectiveness 岡崎一真, 加藤遥平, 和泉早智子, 千崎可奈子 Journal of Japanese Society of Pharmaceutical Oncology 20: 65-65, 2021. |
|---|
|
|
P-029. Evaluation of the validity in making and the case expansion of the new metrics for the oxaliplatin (L-OHP) origin-related feeling cold hypersensitivity symptom 橋本竜, 佐藤淳也, 前澤佳代子, 百瀬泰行 Journal of Japanese Society of Pharmaceutical Oncology 20: 66-66, 2021. |
|---|
|
|
P-030. Adverse event investigation of the Abemaciclib in the true clinical practice 山中紗弥花, 高武嘉道, 木村滋, 福石和久, 川俣洋生, 高島伸也 Journal of Japanese Society of Pharmaceutical Oncology 20: 67-67, 2021. |
|---|
|
|
P-031. The making of the side effect check sheet at use of immune checkpoint inhibitor and the evaluation 鈴木芳, 中原良介, 龍田涼佑, 田中遼大, 伊東弘樹 Journal of Japanese Society of Pharmaceutical Oncology 20: 68-68, 2021. |
|---|
|
|
P-032. Examination about relations of the nutritional index and effectiveness six weeks after the Nivolumab administration 加藤遥平, 岡崎一真, 千崎可奈子, 和泉早智子 Journal of Japanese Society of Pharmaceutical Oncology 20: 69-69, 2021. |
|---|
|
|
P-033. About aprepitant combined effect for retching vomiting of the GCD therapy 松下尚弘, 桑崎綾子, 原友子, 古賀清弘, 黒木吟美, 田中早穂子, 町田梨絵子, 石丸隆之, 野中敏治 Journal of Japanese Society of Pharmaceutical Oncology 20: 70-70, 2021. |
|---|
|
|
P-035. The expression of infusion reaction situation investigation of the Obinutuzumab in the Osaka country cancer center 田中佐季, 角川幸男, 中野寛之, 高木麻里, 吉田智江, 藤田敬子 Journal of Japanese Society of Pharmaceutical Oncology 20: 72-72, 2021. |
|---|
|
|
P-036. Does profit match the hospitalized peg filgrastim administration? 櫻井雄一郎, 大迫絢加, 井上美菜, 東元一晃, 有馬純子 Journal of Japanese Society of Pharmaceutical Oncology 20: 73-73, 2021. |
|---|
|
|
P-037. Approach of the dose confirmation with the capecitabine inspection support paper in the health insurance pharmacy 吉田貴大, 辻真利, 山田裕介, 笹野寿基, 竹原美穂, 安川徹, 西阪宏彰, 辻宗一郎 Journal of Japanese Society of Pharmaceutical Oncology 20: 74-74, 2021. |
|---|
|
|
P-038. Effect ... of providing treatment precedent fact-finding - tyrosine kinase inhibitor of the hypothyroidism in the nephrocyte cancer nivolumab application case 勝山里佳, 吉野真樹, 佐々木奈穂, 田川千明, 大平直樹, 竹内克己, 布澤恵里香, 田中克幸, 齋藤和歌子, 田中佳美, 山下弘毅, 石井良, 木村宏之 Journal of Japanese Society of Pharmaceutical Oncology 20: 75-75, 2021. |
|---|
|
|
P-039. Analysis of the diarrhea expression risk factor in naldemedine treated patients 寺田公介, 中島寿久, 阿部健太郎, 齋藤義正, 赤木徹, 橋本浩伸, 近野健一, 山口正和 Journal of Japanese Society of Pharmaceutical Oncology 20: 76-76, 2021. |
|---|
|
|
P-040. The current situation investigation of postponement of weight loss, administration skip, administration/interruption of GEM+nab-PTX in our hospital 宇山佳奈, 山本幸二郎, 岡村央, 畠山成寛, 川邉桂, 古川大輔, 小池博文, 佐橋幸子 Journal of Japanese Society of Pharmaceutical Oncology 20: 77-77, 2021. |
|---|
|
|
P-041. We look at the effectiveness of the bevacizumab combination in the trifluridine/Tipiracil therapy and the rear of the pharmacist intervention and examine a mark 原伸輔, 坂井大介, 山本智也, 佐藤太郎, 奥田真弘 Journal of Japanese Society of Pharmaceutical Oncology 20: 78-78, 2021. |
|---|
|
|
P-042. Estimate of the effect of treatment of the overall survival using RMST/RMTL in the immune checkpoint inhibitor 田中奈波, 前島多絵, 渡邊真知子, 板垣文雄 Journal of Japanese Society of Pharmaceutical Oncology 20: 79-79, 2021. |
|---|
|
|
P-043. Effect on renal function by the diuretics change of the cisplatin short hydration regimen 中村俊之, 本郷修也, 大岡千寿子, 野洌孝二, 小室太郎 Journal of Japanese Society of Pharmaceutical Oncology 20: 80-80, 2021. |
|---|
|
|
P-044. Examination about the safety of the Palbociclib in elderly people 坂本竜平, 向井淳治, 濱崎淳哉, 小竹優希, 竹原涼子, 奥田広志 Journal of Japanese Society of Pharmaceutical Oncology 20: 81-81, 2021. |
|---|
|
|
P-045. Investigation of the nutritional factor to give adjuvant chemotherapy introduction after the pancreatic cancer technique 菊地義明, 鈴木直哉, 朝倉幹己, 藤田果那, 庄崎沙耶, 田中耕太, 木下愛, 山本翔太, 山田将吾, 前川英輝, 藤林遼, 高橋誠, 青田忠博 Journal of Japanese Society of Pharmaceutical Oncology 20: 82-82, 2021. |
|---|
|
|
P-046. Blood drug levels monitoring of the Teicoplanin in patients with pediatric malignancy 有馬崇充, 佐野智望, 新藤美香, 赤木徹, 橋本浩伸, 近野健一, 塩塚美歌, 小林治, 岩田敏, 山口正和 Journal of Japanese Society of Pharmaceutical Oncology 20: 83-83, 2021. |
|---|
|
|
P-047. Examination IV of the improvement mechanism by the minocycline application of the dermatopathy by Afatinib 佐野和美, 近藤直樹, 泉悠人, 吉川桃香, 齋藤榛夏, 西澤燿, 西嶌秀幸 Journal of Japanese Society of Pharmaceutical Oncology 20: 84-84, 2021. |
|---|
|
|
P-048. Example that led to prescription suggestion from the medication follow-up of the drugstore pharmacist to patients who received cancer chemotherapy 臼井孝 Journal of Japanese Society of Pharmaceutical Oncology 20: 85-85, 2021. |
|---|
|
|
P-049. 1 case of the childhood intracranial malignant melanoma which aimed at the home care after the nivolumab administration 勝連真人, 垣花真紀子 Journal of Japanese Society of Pharmaceutical Oncology 20: 86-86, 2021. |
|---|
|
|
P-050. Safe investigation about the administration time when we gave an initial dose at trastuzumab, pertuzumab resumption 遠藤秀竜, 加藤貴由, 中島彩子, 見尾谷昇, 山崎崇 Journal of Japanese Society of Pharmaceutical Oncology 20: 87-87, 2021. |
|---|
|
|
P-051. Effect on bone density investigation with the intermittent steroid of the antiemesis purpose in the CAPOX therapy 下別府郁子, 堀麻衣, 藤原華乃子, 牛島美里, 山先恵里加, 江川可奈, 井上真理子, 小間井祥代, 生本太郎, 小高雅人 Journal of Japanese Society of Pharmaceutical Oncology 20: 88-88, 2021. |
|---|
|
|
P-052. Use of in-line filter advisability at the nanoliposomal type irinotecan administration 中村俊貴, 岩田耕一郎, 左右田和枝, 柴田壮一, 松原肇 Journal of Japanese Society of Pharmaceutical Oncology 20: 89-89, 2021. |
|---|
|
|
P-053. The example that contributed to safe continuation of the chemotherapy foreign display of the extensive pharmacy management function of the drugstore pharmacist 白戸達介, 谷口雅洋, 畔柳裕一, 石黒貴子, 前田守, 長谷川佳孝, 月岡良太, 森澤あずさ, 大石美也 Journal of Japanese Society of Pharmaceutical Oncology 20: 90-90, 2021. |
|---|
|
|
P-054. 1 case that developed Listeria monocytogenes meningitis during daratumumab administration 新倉匠, 大谷隆之, 中田吉則, 河井良智 Journal of Japanese Society of Pharmaceutical Oncology 20: 91-91, 2021. |
|---|
|
|
P-055. 2 case ... that pharmacy management - telephone follow for the foreign cancer chemotherapy patients in the health insurance pharmacy was effective 佐村頼寿 Journal of Japanese Society of Pharmaceutical Oncology 20: 92-92, 2021. |
|---|
|
|
P-056. One case that contents change of the fluid therapy to use together affected the flow rate precision of the portable disposable infusion pump in the cancer chemotherapy 鷹野理, 安井紗緒里, 秋田菜々世 Journal of Japanese Society of Pharmaceutical Oncology 20: 93-93, 2021. |
|---|
|
|
P-057. Study on administration cancellation event of the use of S one preparation patients in our hospital 佐藤晃, 池田舞, 中野里美, 持田知志, 平島麻由美, 石黒裕樹, 真島みなみ, 横山恒, 山田明 Journal of Japanese Society of Pharmaceutical Oncology 20: 94-94, 2021. |
|---|
|
|
P-058. Use experience of the improved Mohs paste (Mohs parent water cream) for the head and neck malignant tumor 黒崎隆, 佐藤淳也, 橋本竜, 竹内秀之, 守田侑真, 入野真紀, 梅田鈴香, 塚越真由美, 山田祐 Journal of Japanese Society of Pharmaceutical Oncology 20: 95-95, 2021. |
|---|
|
|
P-059. About current situation and irAE of the checkpoint inhibitor administration in the small and medium size hospital of immunity 川田亮, 春原龍矢 Journal of Japanese Society of Pharmaceutical Oncology 20: 96-96, 2021. |
|---|
|
|
P-060. Examination about the safety of the trastuzumab Biosimilar preparation 三浦宏真, 佐々木悠稀, 高橋慎太郎, 菊池亮大, 三浦清彦 Journal of Japanese Society of Pharmaceutical Oncology 20: 97-97, 2021. |
|---|
|
|
P-061. 3 cases that was available for ambulatory care of Blinatumomab using a portable spirit smuggling liquid pump 堀沢知世, 井上裕貴, 佐藤菜月, 関水匡大, 小須田幸江, 服部浩佳, 前田尚子, 下地園子, 飯田浩充, 永井宏和, 中井正彦 Journal of Japanese Society of Pharmaceutical Oncology 20: 98-98, 2021. |
|---|
|
|
P-062. 1 case that acute renal failure developed by EMACO therapy for choriocarcinoma and dialyzed 陣内優, 畑瀬圭佐, 有冨航平 Journal of Japanese Society of Pharmaceutical Oncology 20: 99-99, 2021. |
|---|
|
|
P-063. 1 case that adherence improved by the medication support to acute lymphoid leukemia (ALL) children 赤嶺美奈, 赤嶺有希子, 加納美知子, 佐久間美里, 高木正信, 田中祥子, 松尾律子, 山本美智子, 吉原澄吉, 谷田弘, 澤井一 Journal of Japanese Society of Pharmaceutical Oncology 20: 100-100, 2021. |
|---|
|
|
P-064. One case of the epithelium squamous non-small cell lung cancer which developed hypomagnesemia during Necitumumab administration 井上竜一, 五十嵐保陽, 真島宏太, 角康隆, 大倉野将広, 江越菜月, 井上貴文, 川田哲史, 柿本秀樹, 西田恵美, 長郷あかね, 兼重晋, 緒方憲太郎, 神村英利 Journal of Japanese Society of Pharmaceutical Oncology 20: 101-101, 2021. |
|---|
|
|
P-065. Example that combination of rifampicin was started during Lenvatinib remedy 矢部和昭, 藤田あゆみ, 松本憲昭, 末次加代子, 吉田達司, 庄瀬篤志, 杉浦伸哉, 杉浦克典 Journal of Japanese Society of Pharmaceutical Oncology 20: 102-102, 2021. |
|---|
|
|
P-066. Use investigation of the Lenvatinib in the hepatocellular carcinoma in our hospital 山田早, 山中佑也, 土屋裕伴, 新井亘, 増田裕一 Journal of Japanese Society of Pharmaceutical Oncology 20: 103-103, 2021. |
|---|
|
|
P-067. The case that medication support was possible by the telephone follow-up to the anticancer agent remedy patients 清水友香 Journal of Japanese Society of Pharmaceutical Oncology 20: 104-104, 2021. |
|---|
|
|
P-068. Example that led to discontinuation weight loss for image transmitter Yoshikatsu of the prescription notebook application with the chat consultation function more 庄瀬篤志, 藤田あゆみ, 末次加代子, 矢部和昭, 杉浦伸哉 Journal of Japanese Society of Pharmaceutical Oncology 20: 105-105, 2021. |
|---|
|
|
P-069. The drug interactions that we experienced by the supportive care to patients with colon cancer during the mFOLFOX+Cet therapy enforcement 河端明子, 藤田あゆみ, 杉浦伸哉 Journal of Japanese Society of Pharmaceutical Oncology 20: 106-106, 2021. |
|---|
|
|
P-070. Side effect investigation every the PD-L1 frequencies in patients receiving immune checkpoint inhibitor 岡原愛, 龍田涼佑, 田中遼大, 伊東弘樹 Journal of Japanese Society of Pharmaceutical Oncology 20: 107-107, 2021. |
|---|
|
|
P-071. The case that hiccups improved by the intervention of the pharmacist for patients receiving oxaliplatin 芦名正生, 上野誠子, 鈴木景就, 小野徹, 一野勇太, 笠井一憲, 青木有希子, 村川麻里子, 中村圭介, 寺嶋望, 又村健太, 松倉瑞希 Journal of Japanese Society of Pharmaceutical Oncology 20: 108-108, 2021. |
|---|
|
|
P-072. Intervention to patients with CIPN onset utilizing the telephone follow-up 末次加代子, 藤田あゆみ, 杉浦伸哉, 杉浦克典 Journal of Japanese Society of Pharmaceutical Oncology 20: 109-109, 2021. |
|---|
|
|
P-073. An example of the telephone follow-up for patients with lung cancer during the DTX enforcement 宮田香織, 藤田あゆみ, 武野慎也, 杉浦伸哉 Journal of Japanese Society of Pharmaceutical Oncology 20: 110-110, 2021. |
|---|
|
|
P-074. One patient who contributed to blood pressure management of the pazopanib therapy by the telephone follow-up 岩田章宏, 藤田あゆみ, 杉浦伸哉, 杉浦克典 Journal of Japanese Society of Pharmaceutical Oncology 20: 111-111, 2021. |
|---|
|
|
P-075. 1 case that developed Candida liver abscess during pancreatic cancer chemotherapy 北野陽子, 谷香保里, 指田麻未 Journal of Japanese Society of Pharmaceutical Oncology 20: 112-112, 2021. |
|---|
|
|
P-076. One case that presented disturbance of consciousness due to the hyperammonemia and convulsions after the mFOLFOX6 therapy enforcement 川澄美子, 下澤辰哉, 飯塚友梨, 五日市宏, 菊池知美 Journal of Japanese Society of Pharmaceutical Oncology 20: 113-113, 2021. |
|---|
|
|
P-077. One patient who presented with a retching symptom during CBDCA+PEM+Pembrolizumab maintenance therapy for the non-small cell lung cancer 屋敷大輔, 森永崇史, 池沢若菜, 田中恭人, 豊留麻衣, 北園幸大, 中野一馬, 山本梢, 淵脇ゆかり, 徳丸章佳, 長ヶ原琢磨, 荻尾夕起子, 岸本真 Journal of Japanese Society of Pharmaceutical Oncology 20: 114-114, 2021. |
|---|
|
|
P-078. Investigation of the onset of interstitial pneumonia situation in patients receiving immune checkpoint inhibitor 川島悠吾, 村嶋彩加, 宗本尚子, 鳥居奈央, 鶴島真子, 瓦比呂子, 徳山洋子 Journal of Japanese Society of Pharmaceutical Oncology 20: 115-115, 2021. |
|---|
|
|
P-079. 1 case that evaded the becoming severe of the adverse event by patients follow-up 都和彦, 田村知子, 近藤万友美, 高子優子, 吉岡睦展 Journal of Japanese Society of Pharmaceutical Oncology 20: 116-116, 2021. |
|---|
|
|
P-080. Examination about the effect on safety and pharmacist duties by the change to the once a day administration of busulfan method in the allogeneic hematopoietic stem cell transplantation 橋本直美, 堀口大輔, 松山淳史, 鬼丸俊司, 中野伸亮, 伊藤能清 Journal of Japanese Society of Pharmaceutical Oncology 20: 117-117, 2021. |
|---|
|
|
P-081. The use results and side effect investigation of the Nivolumab+Ipilimumab therapy in our hospital 杉慎介, 川野昭, 福重昇吾, 田代聡美, 藤永理恵子 Journal of Japanese Society of Pharmaceutical Oncology 20: 118-118, 2021. |
|---|
|
|
P-082. 1 case that was given switching to methadone hydrochloride for the case that had difficulty with elimination of pain based on hydromorphone 豊留麻衣, 田中恭人, 森永崇史, 池沢若菜, 北園幸大, 中野一馬, 山本梢, 屋敷大輔, 淵脇ゆかり, 徳丸章佳, 長ヶ原琢磨, 荻尾夕起子, 岸本真 Journal of Japanese Society of Pharmaceutical Oncology 20: 119-119, 2021. |
|---|
|
|
P-083. 1 case that Colin symptom in the colon cancer FOLFIRI+Bevacizumab therapy relieved by administration of butylscopolamine 田中康裕, 西直人 Journal of Japanese Society of Pharmaceutical Oncology 20: 120-120, 2021. |
|---|
|
|
P-084. 1 case that came by early detection for hypothyroidism and adrenal cortical insufficiency by the multi-type of job cooperation 尾崎智規, 武知理菜子, 中川智章, 森田淳子, 堀智貴, 御堂恵里佳, 牧浦耕平, 吉岡奈津恵, 中谷充宏, 生島繁樹 Journal of Japanese Society of Pharmaceutical Oncology 20: 121-121, 2021. |
|---|
|
|
P-085. One case that was able to evade combination of Abemaciclib and carbamazepine by a telephone follow-up 広瀬美穂, 矢部和昭, 藤田あゆみ, 杉浦伸哉, 杉浦克典 Journal of Japanese Society of Pharmaceutical Oncology 20: 122-122, 2021. |
|---|
|
|
P-086. One case that a drugstore pharmacist visited the doctor's patient regularly, and took medicine, and supported you, and was able to preserve the medication situation of the oral anticancer medicine well 金野泰, 鮎川修, 加治屋忠一 Journal of Japanese Society of Pharmaceutical Oncology 20: 123-123, 2021. |
|---|
|
|
P-087. 2 cases that was consulted from the anticancer medicine remedy patients during a medication period, and intervened about supportive care medicine 本田沙織 Journal of Japanese Society of Pharmaceutical Oncology 20: 124-124, 2021. |
|---|
|
|
P-088. Examination of the low-dose methadone addition case to opioid patients with intractable cancer pain using 國東佑美, 山内紗綾香, 田中雅子, 藤原康浩, 岸本靜佳, 鹿島孝子 Journal of Japanese Society of Pharmaceutical Oncology 20: 125-125, 2021. |
|---|
|
|
P-089. Grasp and efforts of the needs of patients with cancer for a drugstore, the pharmacist 澤井一, 赤嶺美奈, 赤嶺有希子, 加納美知子, 佐久間美里, 高木正信, 田中祥子, 松尾律子, 山本美智子, 吉原澄吉, 谷田弘 Journal of Japanese Society of Pharmaceutical Oncology 20: 126-126, 2021. |
|---|
|
|
P-090. Efforts for patients with at-home cancer in the local health insurance drugstore 佐々木直子 Journal of Japanese Society of Pharmaceutical Oncology 20: 127-127, 2021. |
|---|
|
|
P-091. Efforts to the treatment at home at the cancer special hospital door front drugstore 照屋千津子, 野々原育子, 土橋美和, 岸みゆき, 加藤貴昭 Journal of Japanese Society of Pharmaceutical Oncology 20: 128-128, 2021. |
|---|
|
|
P-092. Cancer chemotherapy, palliative care to support by an at-home team 岩崎章吾 Journal of Japanese Society of Pharmaceutical Oncology 20: 129-129, 2021. |
|---|
|
|
P-093. Examination about the decontamination effect of the anticancer agent by the ultraviolet irradiation 中石真由美, 中西弘和 Journal of Japanese Society of Pharmaceutical Oncology 20: 130-130, 2021. |
|---|
|
|
P-094. Efforts for the disposal reduction after the anticancer agent preparation 伊東充, 四方公亮, 桝早紀子, 井上由紀, 佐藤香織, 勝俣はるみ Journal of Japanese Society of Pharmaceutical Oncology 20: 131-131, 2021. |
|---|
|
|
P-095. Efforts and anticancer agent exposure investigation to occupational exposure in the hepatic artery chemistry embolus therapy 前田健太, 杉村ゆかり, 寺舘圭祐, 宮越貴之, 佐久間明洋, 片田竜司 Journal of Japanese Society of Pharmaceutical Oncology 20: 132-132, 2021. |
|---|
|
|
P-096. About the introduction to all anticancer medicine preparations of the closed system anesthesia drug transportation system and the effect 渋江理恵, 陶山登之, 石原慎之, 玉木宏樹, 矢野貴久, 直良浩司 Journal of Japanese Society of Pharmaceutical Oncology 20: 133-133, 2021. |
|---|
|
|
P-097. From improvement in quality of the medication counseling to the foreign cancer chemotherapy patients at the health insurance pharmacy to "specific drug management instruction addition 2" calculation 和田憲周, 林智子, 山本侑記, 藤井美和子 Journal of Japanese Society of Pharmaceutical Oncology 20: 134-134, 2021. |
|---|
|
|
P-098. It is ... from relation ... examination of the immune checkpoint inhibitor set order for the proper use to professional player representation examination order Thor making by the pharmacist 原田典和, 合田綾子, 佐野嘉代子, 片桐将志, 中西順子, 篠永浩, 遠藤出, 神野秀基, 前田宏也, 加地努 Journal of Japanese Society of Pharmaceutical Oncology 20: 135-135, 2021. |
|---|
|
|
P-099. Anticancer agent preparation before and after the closed system anesthesia drug transportation system (CSTD) introduction and exposure to administration environment situation comparison 羽賀博昭, 上村賢介, 高橋由美, 内坪誉歳, 武者信行 Journal of Japanese Society of Pharmaceutical Oncology 20: 136-136, 2021. |
|---|
|
|
P-100. Efforts of the pharmacy for the enforcement situation investigation and the improvement of the hepatitis B onset prophylaxis in the cancer chemotherapy in rate of use 江原美里, 畑裕基, 川上智久, 宮城和代, 井上敦介, 宮部貴識, 山内一恭 Journal of Japanese Society of Pharmaceutical Oncology 20: 137-137, 2021. |
|---|
|
|
P-101. About making of accessibility and the maintenance-related expensive "prescription & preparation table with the function to automatically calculate" issuance software 岸本真, 屋敷大輔, 田中恭人, 森永崇史, 池沢若菜, 豊留麻衣, 北園幸大, 中野一馬, 山本梢, 淵脇ゆかり, 徳丸章佳, 長ヶ原琢磨, 荻尾夕起子, 三阪高春 Journal of Japanese Society of Pharmaceutical Oncology 20: 138-138, 2021. |
|---|
|
|
P-102. The making of the anticancer medicine checking prescription tool and the effect 松尾奏江, 石渡宏平, 増淵麻実, 川口敦美, 和田実佳子, 黒木あかね, 秦哲磨, 疋田絵梨, 大崎真美, 賀川智子, 城田幹生 Journal of Japanese Society of Pharmaceutical Oncology 20: 139-139, 2021. |
|---|
|
|
P-103. Evaluation of the duties improvement at anticancer agent formulations 前田美紀, 生田和之, 加藤一郎 Journal of Japanese Society of Pharmaceutical Oncology 20: 140-140, 2021. |
|---|
|
|
P-104. Efforts of the pharmacist to HBV reactivation prevention with the cancer medical therapy 大木崇弘, 野村淳, 石田岳史 Journal of Japanese Society of Pharmaceutical Oncology 20: 141-141, 2021. |
|---|
|
|
P-105. Creation and dissemination activities of spill kits aimed at preventing the spread of pollution when exposed to anticancer drugs 宮内輝人, 橋本竜, 吉成宏顕, 鈴木茉莉子, 梅田鈴香, 入野真紀, 黒崎隆, 伊藤裕子, 塚越真由美, 佐藤淳也 Journal of Japanese Society of Pharmaceutical Oncology 20: 142-142, 2021. |
|---|
|
|
P-106. The HBV reactivation measures enforcement situation investigation in the cancer chemotherapy 海野祥生, 生田和之, 寺島聡子, 高木淳也, 前田美紀, 加藤一郎 Journal of Japanese Society of Pharmaceutical Oncology 20: 143-143, 2021. |
|---|
|
|
P-107. Efforts for the anticancer agent preparation duties efficiency 寺島聡子, 生田和之, 高木淳也, 海野祥生, 加藤一郎 Journal of Japanese Society of Pharmaceutical Oncology 20: 144-144, 2021. |
|---|
|
|
P-108. Examination of the review of questionnaire results of the training for the extravasation and the correspondence manual 佐藤浩二, 吉田咲紀, 植田真理, 小西千尋, 松浦暢子, 島田敏江, 小野優子, 浅井真由美, 佐藤美代子, 長谷圭吾 Journal of Japanese Society of Pharmaceutical Oncology 20: 145-145, 2021. |
|---|
|
|
P-109. The development of the doubt inquiry standard in the foreign chemotherapy and change of doubt inquiry 田辺就子, 中村俊貴, 松原肇 Journal of Japanese Society of Pharmaceutical Oncology 20: 146-146, 2021. |
|---|
|
|
P-110. The environmental exposure investigation of the anticancer agent which we performed from 2016 through 2020 and inspection of exposure measures 朝居初奈, 山川智一, 杉本央司, 加藤恵一 Journal of Japanese Society of Pharmaceutical Oncology 20: 147-147, 2021. |
|---|
|
|
P-111. Examination about the usefulness of the regimen checking prescription support system in the cancer chemotherapy 三井満里奈, 森田一, 平田藍, 松崎貴志, 田中恒明 Journal of Japanese Society of Pharmaceutical Oncology 20: 148-148, 2021. |
|---|
|
|
P-112. Efforts of the examination order support based on PBPM in the foreign chemotherapy 日比野三紗子, 平井成和, 佐野君芳, 増田雅行 Journal of Japanese Society of Pharmaceutical Oncology 20: 149-149, 2021. |
|---|
|
|
P-113. Anticancer agent exposure monitoring 松浦徹, 與田賢作, 大汐欣輝, 市川美佳, 村田智弘, 奥野美和, 内山有理香, 矢野洋平, 平川雅章 Journal of Japanese Society of Pharmaceutical Oncology 20: 150-150, 2021. |
|---|
|
|
P-114. Examination of the cleaning method in the isolator 吉川里香, 田村昌三, 福嶋浩一, 石本学司, 奥野昌宏, 田中詳二 Journal of Japanese Society of Pharmaceutical Oncology 20: 151-151, 2021. |
|---|
|
|
P-115. Comparison of the quantity of fluorouracil included in Tegafur combination OD tablets 高見陽一郎, 岡田奈緒, 八田光平, 久岡真子, 吉井圭佑, 毎熊隆誉, 島田憲一 Journal of Japanese Society of Pharmaceutical Oncology 20: 152-152, 2021. |
|---|
|
|
P-116. Exposure measures effect by the closed system anesthesia administration route introduction at the anticancer medicine administration 菊池健, 渡邉大毅, 相馬貴史, 岡本麻子, 折出洋子, 石原敏道, 柴山良彦, 鶴山辰 Journal of Japanese Society of Pharmaceutical Oncology 20: 153-153, 2021. |
|---|
|
|
P-117. About the duties contents of the pharmacist in the national cancer research center each species Ethical Review Board 西川千晶, 山下紀子, 近野健一, 山口正和 Journal of Japanese Society of Pharmaceutical Oncology 20: 154-154, 2021. |
|---|
|
|
P-118. Fact-finding about the effect that foreign cancer chemotherapy bed reservation system introduction gives in patients waiting time 中川雅史, 泉本裕実, 宮内美奈絵, 喜多由紀, 毛利萌, 樫葉利人 Journal of Japanese Society of Pharmaceutical Oncology 20: 155-155, 2021. |
|---|
|
|
P-119. Usefulness and problem of the Hiroshima University Hospital original clinical study information database based on the oncogene panel test result 板村亮, 本永正矩, 岡本渉, 小林遼平, 寺谷祐亮, 佐伯康之, 松尾裕彰, 檜井孝夫 Journal of Japanese Society of Pharmaceutical Oncology 20: 156-156, 2021. |
|---|
|
|
P-120. Activity report of the pharmacist outpatient performing in 131 beds of hospitals 堀麻衣, 下別府郁子, 藤原華乃子, 山先恵里加, 江川可奈, 牛島美里, 井上真理子, 前田恵美子, 小高雅人 Journal of Japanese Society of Pharmaceutical Oncology 20: 157-157, 2021. |
|---|
|
|
P-121. Estimate for appliance costs reduction by the drug standard adjustment at closed system anesthesia connection appliance full-scale introduction 野崎智椰, 計良貴之, 湊川紘子, 田中恒明 Journal of Japanese Society of Pharmaceutical Oncology 20: 158-158, 2021. |
|---|
|
|
P-122. The examination of the drug costs reduction effect by the introduction of the oxaliplatin generic medicine and DVO simulation evaluation 小塚友美子, 寺島聡子, 加藤一郎 Journal of Japanese Society of Pharmaceutical Oncology 20: 159-159, 2021. |
|---|
|
|
P-123. Development of the academic D tailing material for the aperient individualization of patients with cancer in the Chiba west general hospital 木村敦, 河本怜史, 青柳友彦, 都築竜太, 香取哲哉, 岡元るみ子, 清水忠, 出雲貴文, 小茂田昌代 Journal of Japanese Society of Pharmaceutical Oncology 20: 160-160, 2021. |
|---|
|
|
P-124. About the onset of immune-mediated adverse event information in our hospital 奥村俊一, 松尾拓馬, 石原溶子, 吉野公二 Journal of Japanese Society of Pharmaceutical Oncology 20: 161-161, 2021. |
|---|
|
|
P-125. Visualization (the second report) of the information about a molecular target drug and the target molecule for the malignant tumor 板垣文雄, 高宮万梨野, 前島多絵, 渡邊真知子 Journal of Japanese Society of Pharmaceutical Oncology 20: 162-162, 2021. |
|---|
|
|
P-126. Mapping of the information on adverse drug reactions in the molecular target drug and cross-sectional analysis between the drug 戸辺七海, 大沼有由, 前島多絵, 渡邊真知子, 板垣文雄 Journal of Japanese Society of Pharmaceutical Oncology 20: 163-163, 2021. |
|---|
|
|
P-127. Process of the pharmacist introduction of the expert panel in the district hospital in the cancer genomic medicine and problem 小林遼平, 本永正矩, 板村亮, 寺谷祐亮, 佐伯康之, 松尾裕彰 Journal of Japanese Society of Pharmaceutical Oncology 20: 164-164, 2021. |
|---|
|
|
P-128. Examination of the information to be an opportunity to judge the health insurance pharmacy in cancer-treated patients to have a doubt 小竹優希, 向井淳治, 坂本竜平, 竹原涼子, 濱崎淳哉, 奥田広志 Journal of Japanese Society of Pharmaceutical Oncology 20: 165-165, 2021. |
|---|
|
|
P-129. Search of the adverse event that the prognosis of elderly people in the gefitinib using adverse event spontaneous report database (JADER) may worsen 小林加寿子, 藤崎智也, 飯田彩花, 和田麻季子, 日浦寿美子, 小林秀樹, 加藤裕芳 Journal of Japanese Society of Pharmaceutical Oncology 20: 166-166, 2021. |
|---|
|
|
P-130. The use situation investigation of the hydromorphone hydrochloride injection in our hospital 山内紗綾香, 國東佑美, 田中雅子, 藤原康浩, 岸本靜佳, 鹿島孝子 Journal of Japanese Society of Pharmaceutical Oncology 20: 167-167, 2021. |
|---|
|
|
P-131. About the use situation of olanzapine at the treatment with anticancer agent 藤井大和, 永井詩織, 鷲田依美里, 岩切悦子, 丸山直岳, 河合実 Journal of Japanese Society of Pharmaceutical Oncology 20: 168-168, 2021. |
|---|
|
|
P-132. 2 cases that reached the pharmaceutical intervention by telephone medication support (R) and medicine medicine cooperation in foreign cancer treatment utilizing the feedback report 堀龍太郎, 武田輝幸, 山崎友里絵, 田中寿和, 長沼敬子, 木下隆市, 染谷光洋, 長内泰憲, 宮岡勝弘, 谷口亮央, 中島史雄 Journal of Japanese Society of Pharmaceutical Oncology 20: 169-169, 2021. |
|---|
|
|
P-133. The current situation and problem of the cooperation full addition in our hospital 川口文誉, 常木隆史, 金子憲太郎, 川村僚一朗, 河原英子, 小林路子 Journal of Japanese Society of Pharmaceutical Oncology 20: 170-170, 2021. |
|---|
|
|
P-134. Attempt ... of the common evaluation by efforts - STAS-J to the medical drug prescription for the outpatient who applied PBPM in the medical cooperation 徳永愛美, 縄田修一, 日向美羽, 横山和彦, 小貫道子, 脇谷美由紀, 小原君予, 木村祐子, 市村丈典, 市倉大輔, 鈴木信也, 佐々木忠徳 Journal of Japanese Society of Pharmaceutical Oncology 20: 171-171, 2021. |
|---|
|
|
P-135. The calculation situation of specific drug management instruction addition 2 in our drugstore and future problem 竜田都加, 三宅知宏 Journal of Japanese Society of Pharmaceutical Oncology 20: 172-172, 2021. |
|---|
|
|
P-136. Questionary survey about the effect on insurance pharmacist by the regimen label grant 木村大地, 浜口将一, 清水克次, 角川幸男, 高木麻里, 藤田敬子 Journal of Japanese Society of Pharmaceutical Oncology 20: 173-173, 2021. |
|---|
|
|
P-137. Intervention to nail loss of the DTX+RAM therapy 吉田啓太郎, 大窪典子, 雪竹英志, 西園直子, 久保田邦彦, 永崎一樹, 佐多卓也, 落合晋介 Journal of Japanese Society of Pharmaceutical Oncology 20: 174-174, 2021. |
|---|
|
|
P-138. Efforts for the further improvement of cooperation full addition calculation and medicine medicine cooperation 増野貴司, 中山和彦, 塩野智則, 伊藤惇史, 桜沢千世, 堀口裕之, 小幡輝夫 Journal of Japanese Society of Pharmaceutical Oncology 20: 175-175, 2021. |
|---|
|
|
P-139. About efforts of our center in the cooperation full addition 岩切悦子, 永井詩織, 鷲田依美里, 藤井大和, 丸山直岳, 河合実 Journal of Japanese Society of Pharmaceutical Oncology 20: 176-176, 2021. |
|---|
|
|
P-140. It is ... for calculation of the cooperation full addition in efforts - our hospital of the pharmacist in the foreign chemotherapy 堀智貴, 武知理菜子, 中川智章, 森田淳子, 御堂恵里佳, 尾崎智規, 牧浦耕平, 吉岡奈津恵, 福森洋之, 生島繁樹 Journal of Japanese Society of Pharmaceutical Oncology 20: 177-177, 2021. |
|---|
|
|
P-141. About efforts of the cooperation full addition calculation in the municipal shell mound Hospital 山田暁代, 中谷健一, 金子昌平, 中村文美, 谷口嘉宏, 松浪有香, 城野修男 Journal of Japanese Society of Pharmaceutical Oncology 20: 178-178, 2021. |
|---|
|
|
P-142. Making of the information sharing tool between "efforts to cooperation full addition calculation in the foreign cancer chemotherapy" - hospital pharmacy and operational construction ... 檀和貴, 高瀬尚武, 樋本繭子, 新免徹, 田中智也, 近平知亜紀, 立花充美, 濱本悠希, 高原秀典, 三木育子 Journal of Japanese Society of Pharmaceutical Oncology 20: 179-179, 2021. |
|---|
|
|
P-143. The operational situation of "the cooperation letter between foreign chemotherapy institutions" accompanied with the cooperation full addition calculation and future problem 山本圭恵, 山口瑞彦, 加藤諭美, 遠藤正憲 Journal of Japanese Society of Pharmaceutical Oncology 20: 180-180, 2021. |
|---|
|
|
P-144. About the cooperation between the types of job of the foreign cancer chemotherapy in our hospital 青野智恵美, 高木亮 Journal of Japanese Society of Pharmaceutical Oncology 20: 181-181, 2021. |
|---|
|
|
P-145. Case report of the medicine medicine cooperation by intervention and the reporting to cancer-treated patients of the drugstore pharmacist 加藤貴美, 松岡早紀, 加藤佑規, 佐藤綾花, 小栗明莉, 中村亨 Journal of Japanese Society of Pharmaceutical Oncology 20: 182-182, 2021. |
|---|
|
|
P-146. Usefulness evaluation of the efforts of the medicine medicine cooperation in the foreign cancer chemotherapy 阿部雅雄, 中園武宣, 上村理奈, 丸山祐二, 上田健, 森康弘 Journal of Japanese Society of Pharmaceutical Oncology 20: 183-183, 2021. |
|---|
|
|
P-147. About efforts of the medicine medicine cooperation in the cancer medical therapy 久知良礼美, 永田卓也, 喜田昌記, 渡邊亜矢子, 江畠麗, 伊波樹, 柘植縁理佳, 田中章久, 柏原由佳, 田中克巳, 佐々木忠徳 Journal of Japanese Society of Pharmaceutical Oncology 20: 184-184, 2021. |
|---|
|
|
P-148. The acquisition situation and problem of the foreign chemotherapy cooperation full addition in our hospital 小島千佳, 本郷知世, 千葉理恵, 百武宏志, 蟻川勝 Journal of Japanese Society of Pharmaceutical Oncology 20: 185-185, 2021. |
|---|
|
|
P-149. Fact-finding of the reporting book operation in the foreign cancer chemotherapy 野口祥紀, 加藤杏子, 和田亜希, 中西由衣, 小川晃宏, 内田早弓, 三宅知宏, 谷村学 Journal of Japanese Society of Pharmaceutical Oncology 20: 186-186, 2021. |
|---|
|
|
P-150. Fact-finding of the pharmaceutical management to the breast cancer inpatient by the ward pharmacist 渡邊太朗, 小山舞, 礒部邦彌, 名和田幸介, 川中明宏, 白野陽正 Journal of Japanese Society of Pharmaceutical Oncology 20: 187-187, 2021. |
|---|
|
|
P-151. Of the cooperation full addition calculation introduction in the small hospital, actually 吉田幸史, 村井佐和, 平田司, 柴田亜由美, 土谷隆紀 Journal of Japanese Society of Pharmaceutical Oncology 20: 188-188, 2021. |
|---|
|
|
P-152. Inflection situation ... of response to cooperation full addition and result - tracing report 縄田修一, 市村丈典, 市倉大輔, 徳永愛美, 木村祐子, 稲垣彩美, 中川啓子, 鈴木信也, 佐々木忠徳 Journal of Japanese Society of Pharmaceutical Oncology 20: 189-189, 2021. |
|---|
|
|
P-153. Example that evaluated the adverse event for patients during treatment with anticancer medicine using the video call in the health insurance pharmacy 松田枝里, 八木朋美, 村田勇人, 藤田聡, 宮原克明, 千島已幸 Journal of Japanese Society of Pharmaceutical Oncology 20: 190-190, 2021. |
|---|
|
|
P-154. It is ... mainly on bed control duties improvement - fact-finding in the foreign chemotherapy room 生田和之, 寺島聡子, 海野祥生, 高木淳也, 前田美紀, 有賀史絵, 石川美智子, 我妻真理子, 嶋中ますみ, 牛島品子, 加藤一郎 Journal of Japanese Society of Pharmaceutical Oncology 20: 191-191, 2021. |
|---|
|
|
P-155. About the operation of the telephone follow-up using the side effect check sheet of the each regimen and the result 田村圭将, 西垣賢 Journal of Japanese Society of Pharmaceutical Oncology 20: 192-192, 2021. |
|---|
|
|
P-156. Invention to safe administration of the paclitaxel using two dribbling control-type infusion pumps 鶴田和裕, 荒田千奈美, 大室直樹, 吉村光太郎, 山崎久善, 塩地聖一, 久保睦美, 生島五郎 Journal of Japanese Society of Pharmaceutical Oncology 20: 193-193, 2021. |
|---|
|
|
P-157. The calculation situation of the cooperation full addition in the Hamamatsu Red Cross hospital and future problem 二橋智郎, 大窪達午, 小林美絵, 中村正史 Journal of Japanese Society of Pharmaceutical Oncology 20: 194-194, 2021. |
|---|
|
|
P-158. Efforts of the Fukuoka University Hospital for the calculation of the cooperation full addition and attitude survey to the health insurance pharmacy 井上貴文, 五十嵐保陽, 角康隆, 北村大来, 江越菜月, 大倉野将広, 井上竜一, 真島宏太, 柿本秀樹, 大津友紀, 池内忠宏, 緒方憲太郎, 神村英利 Journal of Japanese Society of Pharmaceutical Oncology 20: 195-195, 2021. |
|---|
|
|
P-159. Contribution to community medical care of the pharmacy in the foreign chemotherapy 洞口拓也, 和仁昇, 嶋俊弥, 政井恵, 大澤琢郎, 若田達朗, 上田秀親, 小林和正, 田中知代, 元田美佳, 近藤佑香, 山本和哉, 和仁寿彦, 竹中勝信 Journal of Japanese Society of Pharmaceutical Oncology 20: 196-196, 2021. |
|---|
|
|
P-160. Efforts to the immune-mediated adverse event management tool making by the second report Saitama cancer medical therapy workshop 鈴木栄, 新井隆広, 国吉央城, 鈴木貴之, 武井大輔, 吉野真樹, 渡邊裕之, 中山季昭, 佐野元彦 Journal of Japanese Society of Pharmaceutical Oncology 20: 197-197, 2021. |
|---|
|
|
P-161. ... which plans efforts for the immune-mediated adverse event measures reinforcement and improvement of evaluation - team approach in medical care 高木淳也, 寺島聡子, 生田和之, 海野祥生, 前田美紀, 加藤一郎 Journal of Japanese Society of Pharmaceutical Oncology 20: 198-198, 2021. |
|---|
|
|
P-162. Efforts for the cooperation full addition acquisition 堀口大輔, 橋本直美, 松山淳史, 鬼丸俊司 Journal of Japanese Society of Pharmaceutical Oncology 20: 199-199, 2021. |
|---|
|
|
P-163. Efforts in our hospital pharmacy accompanied with the calculation of the delirium high risk care addition 梅田鈴香, 佐藤淳也, 塚越真由美, 山田祐 Journal of Japanese Society of Pharmaceutical Oncology 20: 200-200, 2021. |
|---|
|
|
P-164. Efforts and analysis ... of operational ... our hospital pharmacy of the tracing report in the cancer chemotherapy 中澤紘, 新津京介, 鈴木栄, 長谷部忠史 Journal of Japanese Society of Pharmaceutical Oncology 20: 201-201, 2021. |
|---|
|
|
P-165. The foreign cancer instruction system architectural efforts utilizing the medicine medicine cooperation 梅谷亮介, 古谷真依子, 阿登大次郎, 小牟田豊, 八代哲也, 東海秀吉 Journal of Japanese Society of Pharmaceutical Oncology 20: 202-202, 2021. |
|---|
|
|
P-166. Approach of the foreign cancer chemotherapeutic drug medicine cooperation in the Kosei society Takeda Hospital 林千麗, 木村麻紀, 立石まゆみ, 山本有宣, 小高奈津美, 藤野香, 山川紘希, 林修平, 建山和代 Journal of Japanese Society of Pharmaceutical Oncology 20: 203-203, 2021. |
|---|
|
|
P-167. The calculation situation of the cooperation full addition and future problem 近藤竜成, 森本真宗, 松浦佑季, 青木寧々, 堀田理帆, 藤原拓也, 小林健太, 島田佳実, 大矢浩之, 近藤正巳 Journal of Japanese Society of Pharmaceutical Oncology 20: 204-204, 2021. |
|---|
|
|
P-168. Examination of the usefulness of the PRO-CTCAE sheet in patients who received foreign cancer chemotherapy 清水敦也, 山佳織, 佐藤秀紀, 長谷川功, 鶴間哲弘 Journal of Japanese Society of Pharmaceutical Oncology 20: 205-205, 2021. |
|---|
